Pappas I S, Niopas I, Tsiftsoglou A S
Department of Pharmaceutical Sciences, School of Health Sciences, Aristotle University of Thessaloniki, Greece.
Anticancer Drug Des. 1992 Apr;7(2):153-61.
A series of ureido derivatives of pyridine (UDPs) were developed as inducers of leukemic cell differentiation. Fifteen agents prepared by coupling aminopyridines with appropriate isocyanates were structurally identified and tested for both antiproliferative and differentiation inducing activity in cultures of murine and human leukemic cells. Five of these lipophilic compounds [2-(3-ethylureido)-pyridine (1), 2-(3-ethylureido)-6-methylpyridine (4), 2,6-bis-(3-ethylureido)-pyridine (7), 2-(3-ethylureido)-5-methylpyridine (14) and 2-(3-ethylureido)-4,5-dimethylpyridine (15)], promoted terminal erythroid maturation of murine erythroleukemia cells (MEL) (95% hemoglobin producing cells) and stimulated hemoglobin synthesis at concentrations as low as 0.075-0.5 mM. These concentrations are 50-70 fold lower than the optimum inducing concentration of hexamethylene bisacetamide (HMBA), a potent known inducer of differentiation. The proportion of cells induced by each ureido derivative of pyridine was concentration-dependent. Moderate inhibition of cell growth was obtained by these agents at optimum inducing concentrations. Agent 1 also stimulated hemoglobin synthesis in 18% of human erythroleukemia K-562 cells and promoted granulocytic differentiation in 24% of human promyelocytic leukemia HL-60 cells. Structure-activity relationships indicate that 7 was the most potent inducer of all UDPs which contain an ethylureido group attached at 2 position of the pyridine ring as a major structural feature needed for inducing activity. These findings indicate that the ureido derivatives of pyridine are a new class of inducers of murine erythroleukemia cells and, to a lesser extent of granulocytic differentiation, of leukemic HL-60 cells in vitro.
开发了一系列吡啶脲基衍生物(UDPs)作为白血病细胞分化诱导剂。通过将氨基吡啶与合适的异氰酸酯偶联制备的15种试剂进行了结构鉴定,并在小鼠和人白血病细胞培养物中测试了其抗增殖和诱导分化活性。其中5种亲脂性化合物[2-(3-乙基脲基)-吡啶(1)、2-(3-乙基脲基)-6-甲基吡啶(4)、2,6-双-(3-乙基脲基)-吡啶(7)、2-(3-乙基脲基)-5-甲基吡啶(14)和2-(3-乙基脲基)-4,5-二甲基吡啶(15)],促进了小鼠红白血病细胞(MEL)的终末红系成熟(产生血红蛋白的细胞达95%),并在低至0.075 - 0.5 mM的浓度下刺激血红蛋白合成。这些浓度比已知的强效分化诱导剂六亚甲基双乙酰胺(HMBA)的最佳诱导浓度低50 - 70倍。每种吡啶脲基衍生物诱导的细胞比例呈浓度依赖性。在最佳诱导浓度下,这些试剂对细胞生长有适度抑制作用。试剂1还在18%的人红白血病K - 562细胞中刺激血红蛋白合成,并在24%的人早幼粒细胞白血病HL - 60细胞中促进粒细胞分化。构效关系表明,7是所有UDPs中最有效的诱导剂,其主要结构特征是在吡啶环的2位连接一个乙基脲基作为诱导活性所需的基团。这些发现表明,吡啶脲基衍生物是一类新型的小鼠红白血病细胞诱导剂,在较小程度上也是体外白血病HL - 60细胞粒细胞分化的诱导剂。